Oramed trial of diabetes drug delivery tech enrolling patients; Feds give NYU grant to study siRNA;

> Israel's Oramed ($ORMD) said enrollment in the Phase IIb study of its drug delivering capsule for Type 2 diabetes is more than halfway complete. More

> The National Science Foundation awarded New York University's Polytechnic School of Engineering a three-year $300,000 grant to study drug delivery related to siRNA. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.